ArticleFrontiers in oncology2021

Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy.

Yulong Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.